BeOne Medicines Ltd. released its 2026 interim results, reporting a 32.3% year-on-year rise in total revenue to USD 3.22 billion for the six months ended 30 June 2026. Net product sales contributed USD 3.17 billion, driven primarily by oncology therapies BRUKINSA® and TEVIMBRA®.

Gross profit expanded 36.8% to USD 2.88 billion, lifting gross margin on product sales to 89.2% (1H 2025: 86.3%). Research and development expenditure grew 14.6% to USD 1.15 billion, while selling, general and administrative costs rose 15.2% to USD 1.15 billion.

Operating income advanced to USD 574.95 million from USD 98.99 million a year earlier. Net income reached USD 464.36 million, up 385.8% versus 1H 2025, translating to diluted earnings of USD 0.31 per share, or USD 4.01 per ADS.

Key product highlights: • BRUKINSA® revenue climbed 34.5% to USD 2.34 billion—USD 1.65 billion in the United States, USD 378.0 million in Europe, USD 191.2 million in China and USD 119.6 million in other markets. • TEVIMBRA® delivered USD 434.76 million, a 19.2% increase. • In-licensed Amgen products contributed USD 297.11 million, led by XGEVA® at USD 194.42 million.

Balance-sheet cash, cash equivalents and restricted cash totaled USD 5.28 billion at period-end, up from USD 4.61 billion at year-end 2025. Total debt stood at USD 1.07 billion, with a gearing ratio of 20.7% (FY 2025: 23.4%).

Recent milestones include FDA approval of TEVIMBRA® plus ZIIHERA® for first-line HER2-positive gastric cancers, accelerated approval of BCL-2 inhibitor BEQALZI™ for mantle-cell lymphoma, and a USD 300 million manufacturing expansion in New Jersey. BeOne also entered a multi-part collaboration with Revolution Medicines covering RAS-targeted assets.

The Board declared no interim dividend.